Loading clinical trials...
Loading clinical trials...
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy. In step 1 of this study, RAD 001 is given ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06364917 · Non Small Cell Lung Cancer
NCT05076760 · Solid Tumor, Advanced Cancer, and more
NCT07169708 · Non Small Cell Lung Cancer NSCLC
NCT06312137 · Non Small Cell Lung Cancer
NCT07563205 · Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, and more
Georgetown University/Lombardi Cancer Center StudyCoordinator:CRAD001C2114
Washington D.C., District of Columbia
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center
New Orleans, Louisiana
U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office
Dallas, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions